Skip to main content
. 2023 Apr 13;62(5):64. doi: 10.3892/ijo.2023.5512

Figure 1.

Figure 1

Decreased expression of ZCCHC10 is associated with shorter overall survival time in patients with AML. (A) The mRNA expression of ZCCHC10 was measured by reverse transcription-quantitative PCR in nonleukemic and AML patients, ****P<0.0001. (B and C) Expression of the protein encoded by the ZCCHC10 gene in AML cell lines and PBMCs from three healthy donors was determined using western blot analysis (performed in triplicate). The relative band intensity of ZCCHC10 normalized to that of GAPDH is shown as the mean ± SD value. *P<0.05 and **P<0.01 vs. PBMC-3. (D-F) Kaplan-Meier survival curves showing the difference in overall survival between patients with high and low ZCCHC10 expression in the cBioPortal, GEO and TCGA cohorts. AML, acute myeloid leukemia; PBMC, peripheral blood mononuclear cells; GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.